EGFR and cancer: Compound St.49 exhibited significant inhibitory efficacy against the L858R/T790 M mutant EGFR kinase as a reversible inhibitor and can cause apoptosis in a dose-dependent manner, arrest the cell cycle at the G1/G0 phase, and limit the motility of A549 and H1975 cancer cell lines, while compound St.50 exhibited exceptional inhibitory activity and selectivity against the mutant EGFR kinase variants L858R/T790 M/C797S [168].